EX-10.21 2 a2215335zex-10_21.htm EX-10.21Development and Supplemental Agreement • May 5th, 2020 • New York
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Securities and Exchange Commission.
ELAN PHARMA INTERNATIONAL LIMITED AND ACORDA THERAPEUTICS, INC. DEVELOPMENT AND SUPPLEMENTAL AGREEMENT TO AMENDED AND RESTATED LICENSE AGREEMENT DATED 26 SEPTEMBER 2003 AS AMENDED AND SUPPLY AGREEMENT DATED 26 SEPTEMBER 2003Development and Supplemental Agreement • October 25th, 2023 • Alkermes Plc. • Pharmaceutical preparations • New York
Elan Corporation, plc and Acorda are parties to (i) an Amended and Restated License Agreement dated 26 September 2003 pursuant to which, inter alia, Elan Corporation plc granted certain licenses under its intellectual property in respect of mono- and di- aminopyridines (as amended by Amendment No. 1 defined below, the “License Agreement”) and (ii) a Supply Agreement dated 26 September 2003 pursuant to which Elan Corporation agreed to supply Product to Acorda (as amended by Amendment No. 1 defined below, the “Supply Agreement”).
Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Commission.Development and Supplemental Agreement • May 9th, 2011 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
ELAN PHARMA INTERNATIONAL LIMITED AND ACORDA THERAPEUTICS, INC. DEVELOPMENT AND SUPPLEMENTAL AGREEMENT TO AMENDED AND RESTATED LICENSE AGREEMENT DATED 26 SEPTEMBER 2003 AS AMENDED AND SUPPLY AGREEMENT DATED 26 SEPTEMBER 2003
